Clinical Efficacy of Diphenylcyclopropenone Immunotherapy as Monotherapy for Multiple Viral Warts

Park, Jun Yeong; Park, Bok Won; Cho, Eun Byul; Park, Eun Joo; Kim, Kwang Ho

doi:10.1177/1203475418764106

Cited by 8 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a cohort study, 52 albeit the authors didn't explicitly define multiple warts, the presumptive were those patients with more than one warty lesion. In a 2016 case report, 53 the generalized wart was defined as diffuse cutaneous warts over 20 in number that is distributed in more than one area of the body.…”

Section: Resultsmentioning

confidence: 99%

Clinical guideline for the diagnosis and treatment of cutaneous warts (2022)

Zhu

Yang

et al. 2022

J Evidence Based Medicine

View full text Add to dashboard Cite

Aim Cutaneous warts caused by human papillomavirus are benign proliferative lesions that occur at any ages in human lives. Updated, comprehensive and systematic evidence‐based guidelines to guide clinical practice are urgently needed. Methods We collaborated with multidisciplinary experts to formulate this guideline based on evidences of already published literature, focusing on 13 clinical questions elected by a panel of experts. We adopted Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to form classification of recommendations as well as the improved Delphi method to retain respective recommendations with a consensus degree of over 80%. Results Our guideline covered aspects of the diagnosis and treatment of cutaneous warts such as diagnostic gold standard, transmission routes, laboratory tests, treatment principle, clinical cure criterion, definitions, and treatments of common warts, flat warts, plantar warts, condyloma acuminatum, and epidermodysplasia verruciformis. Recommendations about special population such as children and pregnant women are also listed. In total, 49 recommendations have been obtained. Conclusions It is a comprehensive and systematic evidence‐based guideline and we hope this guideline could systematically and effectively guide the clinical practice of cutaneous warts and improve the overall levels of medical services.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical guideline for the diagnosis and treatment of cutaneous warts (2022)

Zhu

Yang

et al. 2022

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

“…----------------------------------------------------------------------------------------------------------------------------------------(A)Topical immunotherapy: 1-Dinitrochlorobenzene: After topical administration, dinitrochlorobenzene is quickly absorbed, and the kidneys are principally responsible for its excretion. It is no longer used in therapeutic settings because it includes pollutants that are carcinogenic and mutagenic to animals (10) .…”

Section: (7)mentioning

confidence: 99%

Immunotherapy Growing Role in Warts Management: Review Article

Ismael¹,

Yousef²,

Elkholy³

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Common dermatological disorders induced by the human papillomavirus (HPV) include warts (both cutaneous and genital). It's not dangerous, but it's unpleasant to look at, can spread to others, and sometimes koebnerizes. So, it's crucial to get the right care at the right time. Several conventional therapies are available, although their efficacy varies. Noninvasive, user-friendly, and showing great promise, topical and systemic immunotherapy has quickly become a mainstay in the treatment of warts. Objective: Assessment of Growing role of immunotherapy in treatment of warts. Methods: We searched PubMed, Google Scholar, and Science Direct for information on Immunotherapy with Warts and human papillomavirus. However, only the most current or comprehensive study from April 2005 to July 2022 was considered. The authors also assessed references from pertinent literature. Documents in languages other than English have been disregarded since there aren't enough resources for translation. Unpublished manuscripts, oral presentations, conference abstracts, and dissertations were examples of papers that weren't considered to be serious scientific research. Conclusion: Intralesional immunotherapy using Candida antigen has the benefits of being inexpensive, showing promise, being simple and easy to inject into a single wart. A promising immunotherapeutic strategy is intralesional injection of the Candida antigen. In both injected and non-injected lesions, this modality is related to Th1 cytokines production.

show abstract

“…Traditionally, a stronger inflammatory reaction was linked to a higher chance of treatment success, since the strong reaction indicates stronger stimulation of the immune system [21,22]. However, some research did not show a correlation between the inflammatory reaction and the therapeutic results [23,24]. Instead, it is the severity of the disease that predicts the outcome of the treatment [25][26][27].…”

Section: The Relationship Between Sensitization and Prognosismentioning

confidence: 99%

“…In 1973, the first use of DNCB contact immunotherapy for resistant warts was reported with a cure rate of 91% [ 28 ]. Thereafter, numerous reports using DNCB, DPCP, and SADBE were published [ 1 , 16 , 21 , 22 , 24 , 28 – 74 ]. Now, contact immunotherapy plays an important role in treating warts, when other options such as chemical destruction (salicylic acid and/or lactic acid topical paints) or physical destruction (liquid nitrogen cryotherapy) show unfavorable results [ 1 ].…”

Section: Topical Immunotherapy In the Treatment Of Skin Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.

show abstract

Clinical Efficacy of Diphenylcyclopropenone Immunotherapy as Monotherapy for Multiple Viral Warts

Abstract: DPCP monotherapy has a lower clinical response than conventional therapy. Initial sensitization to DPCP does not predict a failed response with continued immunotherapy for viral warts.

Cited by 8 publications

References 13 publications

Clinical guideline for the diagnosis and treatment of cutaneous warts (2022)

Clinical guideline for the diagnosis and treatment of cutaneous warts (2022)

Immunotherapy Growing Role in Warts Management: Review Article

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Contact Info

Product

Resources

About